Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9513712 | 1.00 | KDM4E (0.52) | KDM4EMEN1KMT2ARECQLSOAT2 | |
| SCHEMBL31279976 | 1.00 | KDM4E (0.52) | KDM4EMEN1KMT2ARECQLSOAT2 | |
| SCHEMBL10892005 | 1.00 | KDM4E (0.52) | KDM4EMEN1KMT2ARECQLSOAT2 | |
| SCHEMBL9513715 | 1.00 | KDM4E (0.52) | KDM4EMEN1KMT2ARECQLSOAT2 | |
| SCHEMBL1225718 | 0.94 | KDM4E (0.55) | KDM4EMEN1KMT2ARECQLLMNA | |
| SCHEMBL29518581 | 0.94 | KDM4E (0.55) | KDM4EMEN1KMT2ARECQLLMNA | |
| SCHEMBL9565558 | 0.94 | KDM4E (0.55) | KDM4EMEN1KMT2ARECQLLMNA | |
| SCHEMBL4667495 | 0.92 | MEN1 (0.50) | KDM4EMEN1KMT2ARECQLSOAT2 | |
| SCHEMBL4798077 | 0.89 | KDM4E (0.47) | KDM4EMEN1KMT2ARECQLSOAT2 | |
| Salicylic Acid SCHEMBL29596262 | 0.88 | KDM4E (0.49) | KDM4EMEN1KMT2ARECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977725-B1 | NEW FATTY ACID DERIVATIVES | CONPHARMA AS (NO) | 2004-06-16 | — | — | EP | claimed |
| US-20040063677-A1 | Methods of treating disorders using lipophilic derivatives | NORSK HYDRO ASA | 2004-04-01 | — | — | US | claimed |
| US-20030153544-A1 | Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group | CONPHARMA AS (NO) | 2003-08-14 | — | — | US | claimed |
| US-20010006962-A1 | FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 2001-07-05 | — | — | US | claimed |
| US-6762175-B2 | LIPOPHILIC BIOLOGICALLY ACTIVE COMPOUND CONTAINING IN ITS MOLECULAR STRUCTURE ONE OR MORE FUNCTIONAL GROUPS SELECTED FROM ALCOHOL, ETHER, PHENYL, AMINO, AMIDO, THIOL, ACID AND ESTER IN WHICH ONE GROUP IS REPLACED BY LIPOPHILIC GROUP | NORSK HYDRO ASA (NO) | 2004-07-13 | — | — | US | disclosed |
| EP-0977725-B1 | NEW FATTY ACID DERIVATIVES | CONPHARMA AS (NO) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063677-A1 | Methods of treating disorders using lipophilic derivatives | NORSK HYDRO ASA | 2004-04-01 | — | — | US | disclosed |
| US-20030153544-A1 | Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group | CONPHARMA AS (NO) | 2003-08-14 | — | — | US | disclosed |
| US-20010006962-A1 | FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 2001-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006962-A1 | FATTY ACID DERIVATIVES | HADH, NR1H2, NR1H3 | KDM4E 2773/4885MEN1 4825/4885KMT2A 2289/4885 |
| US-20040063677-A1 | Methods of treating disorders using lipophilic derivatives | NCEH1, NR1H2, NR1H3 | KDM4E 3351/4885MEN1 3673/4885KMT2A 2536/4885 |
| US-20030153544-A1 | Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group | TSPO, NR1H2, NR1H3 | KDM4E 3216/4885MEN1 4524/4885KMT2A 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.